Back to Authors

Shah, Meera

https://orcid.org/0000-0002-5359-336X

A5020872528 | I1330342723

Mayo Clinic

Citations 267

TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative cases

American Journal of Hematology | January 19, 2023 | Volume: 98 | Issue: 4 | Pages: No page available

10.1002/ajh.26845 | PMID 36655582

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood | December 27, 2022 | Volume: 141 | Issue: 9 | Pages: 1087-1091

10.1182/blood.2022018236 | PMID 36574363

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience

Blood Advances | December 7, 2022 | Volume: 7 | Issue: 8 | Pages: 1351-1355

10.1182/bloodadvances.2022007937 | PMID 36477202

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4863-4864

10.1182/blood-2022-168053

Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3233-3234

10.1182/blood-2022-167967

Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3235-3236

10.1182/blood-2022-169319

Efficacy of MEK Inhibitors in Erdheim Chester Disease

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9733-9734

10.1182/blood-2022-163674

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6940-6941

10.1182/blood-2022-163518

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561